Last updated 13 days ago

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

340 patients around the world

Available in Argentina, United States

Merck Sharp & Dohme LLC

1Research sites

340Patients around the world

This study is for people with

Alzheimer disease

To 85 Years

All Gender

: Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD).
Has a designated study partner who can fulfill the requirements of this study.
If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening.

: Has a known history of stroke or cerebrovascular disease.
Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically.
Has structural brain disease.
Has a history of seizures or epilepsy within 5 years before screening.
Has any other major central nervous system trauma, or infections that affect brain function.
Has major medical illness or unstable medical condition within 3 months before screening.
Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality.
Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study.
Has a bleeding disorder that is not under adequate control.
Has a history of malignancy occurring within 5 years of screening.
Has a risk factor for corrected QT interval (QTc) prolongation.
Has liver disease.
Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan.
Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision.

Fleni - sede Belgrano

Recruiting

Montañeses 2325, CABA, Buenos Aires

SponsorMerck Sharp & Dohme LLC

Study typeInterventional

Conditions

Alzheimer disease

Requirements

To 85 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07033494